Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes

Obesity Surgery

Volumn 23, Issue 6, 2013, Pages 819-825

  Yska, Jan Peter ^a   Van Der Linde, Susanne ^a   Tapper, Véronique V ^a   Apers, Jan A ^a   Emous, Marloes ^a   Totté, Erik R ^a   Wilffert, Bob ^b,c   Van Roon, Eric N ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bariatric surgery; Drug class; Pharmacoepidemiology; Pharmacokinetics

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; CITALOPRAM; CORTICOSTEROID; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DULOXETINE; ESCITALOPRAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEVOTHYROXINE; LIOTHYRONINE; METFORMIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PRAVASTATIN; PROPRANOLOL; SERTRALINE; SIMVASTATIN; THYROXINE; VENLAFAXINE;

AREA UNDER THE CURVE; BARIATRIC SURGERY; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SOLUBILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTRECTOMY BILLROTH I; GASTRIC BANDING; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; REVIEW; ROUX Y ANASTOMOSIS; SINGLE DRUG DOSE; SLEEVE GASTRECTOMY; STOMACH BYPASS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTITHYROID AGENTS; BARIATRIC SURGERY; CONTRACEPTIVES, ORAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; OBESITY, MORBID; PRACTICE GUIDELINES AS TOPIC;

EID: 84878011287     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0882-6     Document Type: Review

References (58)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-67.
2. Leff DR, Heath D. Surgery for obesity in adulthood. Br Med J. 2009;339:740-6.
3. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: An 18-year report from the International Bariatric Surgery Registry. Am J Surg. 2006;192:657-62.
4. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical complications. Obes Rev. 2010;11:41-50.
5. MacGregor AMC, Boggs L. Drug distribution in obesity and following bariatric surgery: A literature review. Obes Surg. 1996;6:17-27.
6. Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract. 2003;18:131-5.
7. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63:1852-57.
8. Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19:1646-56.
9. Cunningham JL, Merrell CC, Sarr M, et al. Investigation of antidepressant medication usage after bariatric surgery. Obes Surg. 2012;22:530-5.
10. Voelker M, Foster TG. Nursing challenges in the administration of oral antidepressant medications in gastric bypass patients. J Perianesth Nurs. 2007;22:108-24.
11. Seaman JS, Bowers SP, Dixon P, et al. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46:250-3.
12. Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8:62-6.
13. Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169:256-63.
14. Scheen A-J, De Flines J, De Roover A, et al. Bariatric surgery in patients with type 2 diabetes: Benefits, risks, indications and perspectives. Diabetes Metab. 2009;35:537-43.
15. Renard E. Bariatric surgery in patients with late-stage type 2 diabetes: Expected beneficial effects on risk ratio and outcomes. Diabetes Metab. 2009;35:564-8.
16. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and β-cell function in type 2 diabetes. Diabetes Care. 2009;32:514-20.
17. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122:248-56.
18. Dixon JB, Le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379:2300-11.
19. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122-31.
20. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-84.
21. Brancatisano A, Wahlroos S, Matthews S, et al. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis. 2008;4:423-9.
22. Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg. 2012;255:287-93.
23. Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012;99:100-3.
24. Jurowich C, Thalheimer A, Hartmann D, et al. Improvement of type 2 diabetes mellitus (T2DM) after bariatric surgery - who fails in the early postoperative course? Obes Surg. 2012;22:1521-6.
25. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-23.
26. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. NJEM. 2012;366:1577-85.
27. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NJEM. 2012;366:1567-76.
28. Malone M, Alger-Mayer SA. Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother. 2005;39:637-42.
29. Segato G, Busetto L, De Luca M, et al. Weight loss and changes in use of antidiabetic medication in obese type 2 diabetics after laparoscopic gastric banding. Surg Obes Rel Dis. 2010;6:132-7.
30. Maciejewski ML, Livinston EH, Kahwati LC, et al. Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. Surg Obes Rel Dis. 2010;6:601-7.
31. Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21:738-43.
32. Narbro K, Ågren G, Jonsson E, et al. Pharmaceutical costs in obese individuals. Comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: The SOS intervention study. Arch Intern Med. 2002;162:2061-9.
33. Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: Shredding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14:725-30.
34. Nguyen NT, Varela E, Sabio A, et al. Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg. 2006;72:853-6.
35. Makary MA, Clarke JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg. 2010;145:726-31.
36. 2. Obesity. 2011;19:581-7.
37. Ghiassi S, Morton J, Bellatore N, et al. Short-term medication cost savings for treating hypertension and diabetes after gastric bypass. Surg Obes Relat Dis. 2012;8:269-74.
38. Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308:1132-41.
39. Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34:1295-300.
40. Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86:311-8.
41. Skottheim IB, Jakobsen GS, Stormark K, et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther. 2010;87:699-705.
42. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005;19:117-25.
43. Donadelli SP, Salgado W, Marchini JS, et al. Change in predicted 10-year cardiovascular risk following Roux-en-Y gastric bypass surgery: Who benefits? Obes Surg. 2011;21:569-73.
44. Hodo DM, Waller JL, Martindale RG, et al. Medication use after bariatric surgery in a managed care cohort. Surg Obes Rel Dis. 2008;4:601-7.
45. Crémieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. 2010;20:861-70.
46. Wójcicki J, Wojciechowski G, Wójcicki M, et al. Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: A comparative study. Eur J Clin Pharmacol. 2000;56:75-9.
47. Valdivieso A, Calvo R, Gonzalez JP, et al. Influence of several surgical techniques in peptic ulcer disease on the oral kinetic of a basic drug. Acta Chir Belg. 1993;93:88-91.
48. Reddy RC, Baptist AP, Fan Z, et al. The effects of bariatric surgery on asthma severity. Obes Surg. 2011;21:200-6.
49. Sikka N, Wegienka G, Havstad S, et al. Respiratory medication prescriptions before and after bariatric surgery. Ann Allergy Asthma Immunol. 2010;104:326-30.
50. Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril. 2009;92:1501-8.
51. Gerrits EG, Ceulemans R, Van Hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2003;13:378-82.
52. Merhi ZO. Challenging oral contraception after weight loss by bariatric surgery. Gynecol Obstet Invest. 2007;64:100-2.
53. Paulen ME, Zapata LB, Cansino C, et al. Contraceptive use among women with a history of bariatric surgery: A systematic review. Contraception. 2010;82:86-94.
54. Raftopoulos Y, Gagné DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509-13.
55. Fazylov R, Soto E, Cohen S. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644-7.
56. Gniuli D, Leccesi L, Guidone C, et al. Thyroid function and insulin sensitivity before and after bilio-pancreatic diversion. Obes Surg. 2010;20:61-8.
57. Rubio IGS, Galrão AL, Santo MA, et al. Levothyroxine absorption in morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB) surgery. Obes Surg. 2012;22:253-8.
58. Lizer MH, Papageorgeon H, Glembot TM. Nutritional and pharmacologic challenges in the bariatric surgery patient. Obes Surg. 2010;20:1654-9.